Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice

Acute promyelocytic leukemia (APL) is an interesting model for cancer research because of the presence of the specific PML-RARalpha fusion gene associated with the clinical response to retinoic acid differentiation therapy. To better understand and improve differentiation induction with retinoic acid, we have established a human APL-ascites model in SCID mice using the NB4 human APL cell line. NB4 (1 x 10(6) cells) were transplanted into the peritoneum (IP) of SCID mice for 1 month. NB4 ascites cells (A-NB4) appeared, which were then engrafted in SCID mice periodically for 18 passages at an interval of 3 to 4 weeks with a 100% success rate of tumor induction. The mean survival times of SCID mice transplanted with 1 x 10(6) A-NB4 cells was 21.6 +/- 2.3 days. Analysis of the biologic characteristics of ninth passage NB4 ascitic cells was performed and they were found to have the morphologic, immunologic, cytogenetic, and molecular features of cultured NB4 cells. Furthermore, A-NB4 cells were capable of differentiating when treated with all-trans retinoic acid (ATRA), as manifested by enhanced NBT reduction and CD11b expression. In vivo treatment with ATRA in SCID mice for 4 days also increased NBT reduction by A-NB4 cells. ATRA treatment significantly prolonged survival time in the group after transplantation (28.1 +/- 6.8 to 29.1 +/- 8.4 days) compared with the control (P < .001). Furthermore, treatment with adriamycin, an effective chemotherapeutic drug in APL, had a strong growth suppressive effect on A-NB4 cells. These results demonstrate that this SCID-APL (NB4 ascites cells) model is a useful preclinical system for evaluating new or known drugs in the treatment of APL.     

FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo

Most Ig receptors exist as hetero-oligomeric complexes with separate ligand binding (alpha) and signal transducing (beta, gamma, or zeta) subunits. For Fc gamma RIIIa and Fc epsilon RI, association with the FcR gamma-chain is essential for surface expression. However, the human high affinity IgG receptor, hFc gamma RI, was found to be surface- expressed by itself in transient transfection models. We have now analyzed the integrity of hFc gamma RI expression in more detail in stable transfectants. In vitro we noted that, in the absence of FcR gamma-chain, surface expression of hFc gamma RI rapidly declined to background levels, in both IIA1.6 B cells and NIH3T3 fibroblasts. The effect of FcR gamma-chain on hFc gamma RI surface expression in vivo was evaluated by using two newly generated transgenic mouse lines, selectively expressing hFc gamma RI on myeloid cells. These transgenic mice were crossed with FcR gamma-chain-deficient mice. Analysis of blood monocytes and peritoneal macrophages showed that surface expression of hFc gamma RI was reduced by approximately 80%. The remaining approximately 20% of receptors were still capable of binding IgG-opsonized RBC, suggesting FcR gamma-chain not to be critical for hFc gamma RI ligand-binding capacity. Importantly, however, hFc gamma RI signaling capacity was lost in FcR gamma-chain-deficient cells. No phagocytosis could be observed using either ligand sensitized (EA- IgG2a) or CD64-targeted erythrocytes (using a bispecific antibody) in both hFc gamma RI transgenic lines. This documents the FcR gamma-chain to be indispensable for both surface membrane expression and function of human Fc gamma RI in vivo.     

Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A

In vitro studies have demonstrated that cyclosporine A (CsA) acts by inhibiting the phosphatase activity of calcineurin, an important mediator of T-cell activation. The relationship of CsA administration in vivo, calcineurin activity, and graft-versus-host disease (GVHD) has yet to be studied. The calcineurin activities of mononuclear cells isolated from 62 bone marrow transplant recipients and 12 normal volunteers were determined and analyzed with respect to administration of CsA, presence or absence of CsA in plasma, and presence or absence of GVHD. Of 62 patients, 33 were taking CsA and 29 were not. Early posttransplant (< 100 days), the calcineurin activity of patients on CsA was significantly lower than that of patients not on CsA (P = .0004) and than that of normal volunteers (P < .0001). Similarly, late posttransplant (> 100 days), the calcineurin activity of patients taking CsA was inhibited compared with normal volunteers (P < .05). The calcineurin activity of patients with acute GVHD who were taking CsA was lower than that of patients on CsA without acute GVHD matched for time posttransplant (P = .02). Calcineurin activity in patients on CsA with chronic GVHD was similar to those without chronic GVHD on drug. In conclusion, calcineurin activity is significantly suppressed by in vivo administration of CsA. The lower calcineurin activity of patients on CsA with acute GVHD suggests that CsA-resistant GVHD is not the result of inadequate suppression of calcineurin activity. These data suggest that if inhibition of calcineurin is the only physiologic target of CsA administration, simply increasing doses of CsA or treatment with other inhibitors of calcineurin, such as FK506, would not be expected to ameliorate GVHD.     

Risk of gonadoblastoma in female patients with Y chromosome abnormalities and dysgenetic gonads

We report two female patients with gonadal dysgenesis and sex chromosome mosaicism involving the Y chromosome. Conventional karyotyping was supplemented with fluorescent in situ hybridisation techniques in order to confirm the presence of Y chromosomes. One patient is a phenotypic female with karyotype 45,X/46,X,idic(Y)(q11.2). She underwent a laparoscopic gonadectomy at which streak ovaries without evidence of gonadoblastoma were removed. The second patient presented as a virilised female with karyotype 45,X/47,XYY. At laparoscopy, she was found to have mixed gonadal dysgenesis with a gonadoblastoma in situ. We recommend early gonadectomy in female children presenting with gonadal dysgenesis and the presence of a Y chromosome although once the gonadoblastoma locus on Y chromosome gene has been cloned it may be possible to identify those patients who have a low risk of developing gonadoblastoma.     

表皮细胞培养及其临床应用

目的:对表皮细胞的培养方法、临床应用进展方面的研究成果进行综述,展望其发展趋势。资料来源:应用计算机检索PubMed数据库1970-01/2006-08相关表皮细胞的文献,检索词“keratinocytes,culture,skin grafting”,同时检索中国期刊网2000-01/2006-08期间的相关文献,检索词为“表皮细胞,培养,皮肤移植”。资料选择:对资料进行初审,选取相关文献查找全文。纳入标准:①表皮细胞的培养。②表皮细胞的移植。排除标准:综述文献、重复研究类文章。资料提炼:共收集到30篇符合标准的文献,英文文献26篇,中文文献4篇,其中与培养相关的文献19篇,与移植相关的文献11篇。资料综合:自1975年以来,表皮细胞从最初的有血清、有滋养层培养,到无血清、无滋养层培养,再到后来的自动化培养。其培养方法有了较大的发展。这些发展促进了其临床应用,从细胞悬液移植到自、异体细胞膜片移植,再到表皮细胞-生物材料复合物移植。培养和移植方法的发展使人们在治疗大面积皮肤缺损方面看到了希望。结论:目前在表皮细胞培养及其临床应用上还有不少问题需要解决,但随着表皮细胞培养方法和技术的进一步完善,特别是与纳米科学、材料科学等学科的交叉,定能在不远的将来获得理想的永久性皮肤替代物。     

新型长循环紫杉醇脂质体的制备及其细胞毒性

目的:制备一种新型的长循环紫杉醇脂质体,评价其质量,并考察对胃癌细胞(BGC823)的抑制作用。方法:实验于2006-05/11在凯里学院化学系实验室和黔东南州疾病预防控制中心理化科检验室进行。①包封率测定:采用超声薄膜法制备紫杉醇脂质体,用RP-HPLC测定紫杉醇脂质体的药物包封率。②稳定性测定:将紫杉醇脂质体分散在pH为6.5的磷酸缓冲液里,存放在4℃冰箱中30d,观察其包裹量的变化。③对胃癌细胞(BGC823)的抑制作用:MTT法考察在5,10,15,20mg/L4个不同药物浓度下,紫杉醇脂质体对处在对数生长期的BGC823细胞增殖的影响,并用紫杉醇游离药物作为对照。结果:①经RP-HPLC检测,这种长循环紫杉醇脂质体的药物包封率高达97.6%。②紫杉醇脂质体存放在4℃冰箱中,在长达1个月时间内不见絮凝状沉淀,在保存3,8,15,22,30d后,药物在脂质体颗粒中的包裹量分别为97.3%,96.2%,95.6%,94.9%和94.2%,在30d时间里紫杉醇脂质体在缓冲液中的药物泄漏仅有6%。③体外细胞毒性实验表明,5,10,15,20mg/L的紫杉醇注射液对BGC823细胞的抑制率分别为35.24%,48.37%,57.49%,74.84%,而相同药物浓度下的紫杉醇脂质体对BGC823细胞的抑制率为33.46%,44.15%,51.94%,68.64%。结论:①实验置备的紫杉醇脂质体实现了药物的高包封率,而且非常稳定。②紫杉醇药物浓度相同条件下,紫杉醇脂质体对BGC823细胞的抑制率低于游离的紫杉醇药物,说明脂质体对紫杉醇起到了一个很好的缓释作用。